340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |